Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Michelle Bushore, Executive Vice President and Chief Legal Officer of Realty Income (NASDAQ: O), sold 7,400 shares on April 2, 2026, for roughly $461,908. The sale, disclosed in a Form 4 filing with the SEC, followed a period in which Realty Income priced an $800 million senior unsecured note offering, executed a $500 million cross-currency swap, a…
Exxon Mobil (XOM) looks like a pragmatic trade today: deep free cash flow, a conservative balance sheet, and direct exposure to higher oil prices. With crude volatile after renewed Iran tensions, this trade targets a re-test of $175 while capping risk below $152 over a mid-term 45 trading day window.
Daniel C. Keith, a director of Sinclair, Inc. (NASDAQ: SBGI), sold 41,990 shares of Class A Common Stock in three transactions from March 31 to April 2, 2026, realizing about $550,323. After the sales, Keith indirectly holds 25,027 Class A shares through a family trust. The trades come while SBGI shares trade around $13.01, and follow a fourth-quar…
Chris K. Visser, Zumiez Inc.'s Chief Legal Officer and Secretary, sold 9,974 shares of common stock on April 1, 2026, at $22.2139 per share, generating about $221,561. After the sale, Visser holds 43,500 shares. Separately, Zumiez reported fourth-quarter fiscal 2025 results that produced an EPS of $0.78 versus analyst expectations of $1.08, a 27.78…
Bloom Energy Chief Commercial Officer Aman Joshi sold 10,000 Class A shares on April 1, 2026, for $1.35 million under a pre-arranged Rule 10b5-1 trading plan. The company reported 2025 results above its targets, announced a new CFO and received mixed analyst reactions on price targets and ratings. InvestingPro data notes a 601% one-year share price…
22NW Fund, LP executed two sales of L.B. Foster Company (NASDAQ:FSTR) common stock on March 31 and April 1, 2026, disposing of 39,931 shares for roughly $1.11 million. The filings show specific per-share prices, post-transaction holdings, and a joint Form 4 filed by several related entities. These stock sales occur while the company reported mixed …
U.S. stock index futures were modestly higher on Thursday evening as traders prepared for the Good Friday holiday and awaited the U.S. nonfarm payrolls report. Futures for the S&P 500, Nasdaq 100 and Dow Jones were largely unchanged by 20:19 ET (00:19 GMT). Sentiment improved after Iran said it is drafting a maritime protocol with Oman for the Stra…
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson sold 29,900 shares on April 2, 2026, in transactions totaling $1,197,488, while also exercising options to acquire 30,000 shares. The trades were executed under a 10b5-1 plan and occurred as the stock traded close to its 52-week high after strong clinical readouts for retinal therapies p…
Todd M. DuChene, Core Scientific's Chief Legal and Administrative Officer, sold 10,000 shares of the company's common stock on April 1, 2026, generating $152,523. The transaction followed a March 31, 2026 vesting of performance-based restricted stock units and tax-withholding related to that vesting. The company has also expanded its funded commitm…
Microchip Technology (MCHP) is showing early signs of recovery after a deep multi-quarter correction. Revenue momentum, positive booking commentary and a sector-wide semiconductor rally have pushed the stock back above its short-term averages. For traders willing to take a measured risk, an entry near $65.60 with a $60 stop and a $78 target offers …
Grid Dynamics Holdings Inc. (GDYN) Chief Operating Officer Yury Gryzlov sold 1,245 shares on April 2, 2026, under a Rule 10b5-1 plan, netting $6,897. The transaction was disclosed on a Form 4 filing with the SEC. The stock is trading close to its 52-week low and has fallen 59% over the last year. Separately, Grid Dynamics reported fourth-quarter 20…
Adam Crystal, President of Research & Development at Tango Therapeutics (NASDAQ: TNGX), sold 27,000 shares on April 1, 2026, in transactions tied to a pre-established Rule 10b5-1 plan. The sale followed the exercise of stock options and leaves Crystal with 112,622 shares. The company reported sizable 2025 losses, while several analysts reiterated o…
Hinge Health Executive Chairman and Co-Founder Gabriel M.I. Mecklenburg sold 50,000 shares of Class A Common Stock on April 1, 2026, in two tranches for roughly $1.9 million and converted 50,000 Class B shares to Class A that same day. The transaction occurred as the company, valued at $3.03 billion, traded near $38.98, and amid a slate of analyst …
Remitly Global Chief Business Officer Pankaj Sharma sold 10,000 shares on April 1, 2026, for about $152,600 and exercised options to buy 10,000 shares the same day. The company delivered quarterly revenue and adjusted EBITDA ahead of expectations and issued first-quarter fiscal 2026 guidance while updating its leadership team.
Klaviyo Co-CEO and director Andrew Bialecki sold 200,000 shares of Series A common stock on March 31, 2026, generating $3.88 million, and converted 200,000 Series B shares into Series A that same day. The transactions, executed under a Rule 10b5-1 plan adopted May 20, 2025, occur as Klaviyo announces a $500 million repurchase program that includes …
Walter Timothy Winn, Co-COO and EVP of Southland Holdings, Inc. (NASDAQ:SLND), bought 29,177 shares on March 31, 2026, in a transaction worth $42,890. The purchase occurred as the company contends with a large fourth-quarter loss for 2025 and a legal settlement tied to a major convention center expansion project. InvestingPro analysis flags SLND as…
Defense Secretary Pete Hegseth ordered the immediate retirement of Army Chief of Staff Gen. Randy George on April 2, cutting short the general's anticipated four-year term while U.S. military operations against Iran intensify. The removal comes amid a major U.S. strike that partially collapsed a Tehran-area bridge and follows President Donald Trump…
Denali Therapeutics announced Takeda's decision to terminate their collaboration on DNL593, a progranulin replacement therapy for frontotemporal dementia linked to GRN mutations. Denali will continue clinical development independently and plans to report Phase 1/2 study results by the end of 2026. The investigational therapy uses Denali's Transport…
Impact BioMedical Inc. disclosed a 'going concern' qualification in its 2025 10-K audit report highlighting financial uncertainties. Despite this, the company continues with its planned strategic merger with Dr. Ashley's Ltd., anticipated by July 1, 2026.
WW International, Inc. announced the departure of CEO Tara Comonte and has established an Office of the CEO led by senior executives during the search for a permanent successor. The Board formed a Transition Committee to oversee leadership changes and governance matters. Additionally, Debra Cotter was appointed chief legal officer and secretary. Th…
RCM Technologies, Inc. announced robust financial results for the fourth quarter and fiscal year ending January 3, 2026, demonstrating solid growth in revenue, gross profit, and net income compared to the prior year and quarter. The company experienced notable increases in both GAAP and non-GAAP metrics, including a 12.4% revenue growth quarter-ove…
AEON Biopharma announced inducement grants totaling over 990,000 restricted stock units to newly appointed CFO John Bencich. These equity awards are designed to incentivize his employment and align his interests with the company, with vesting tied to his service and AEON's regaining compliance with NYSE American listing standards. The company is fo…
AEON Biopharma announced it received an additional notice from NYSE American indicating non-compliance with an additional listing standard due to stockholders' equity deficit and continued losses. Although this does not immediately impact its listing or previously established compliance plan, failure to regain compliance by August 3, 2026, could le…
Intellia Therapeutics announced inducement grants of 67,150 restricted stock units to 13 new employees as a material inducement to employment under its 2024 Inducement Plan. The RSUs vest over three years and were granted outside the company's stockholder-approved equity plans under Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals granted inducement stock options for 228,500 shares to eight new employees as part of its 2023 Inducement Plan. These options vest over four years and are aimed at attracting and retaining talent to support its cancer therapy pipeline and ongoing clinical trials.
